

7TH EDITION

INNOVATIVE THERAPY,
MONOCLONAL ANTIBODIES
and beyond

Friday, 27 January 2017

Milan

Fondazione IRCCS Istituto Nazionale dei Tumori
Via Giacomo Venezian, 1



Fondazione IRCCS
Istituto Nazionale dei Tumori

Sistema Socio Sanitario



Regione
Lombardia

Under the patronage of Faculty



ANDREA ANICHINI (Istituto Nazionale Tumori, Milano, Italy)

LIONEL APETOH (INSERM Research Center, Dijon, France)

GIOVANNI APOLONE (Istituto Nazionale Tumori, Milano, Italy)

MATTEO BELLONE (Ospedale San Raffaele, Milano, Italy)

MARIO PAOLO COLOMBO (Istituto Nazionale Tumori, Milano, Italy)

FILIPPO DE BRAUD (Istituto Nazionale Tumori, Milano, Italy)

MICHELE DEL VECCHIO (Istituto Nazionale Tumori, Milano, Italy)

MASSIMO DI NICOLA (Istituto Nazionale Tumori, Milano, Italy)

LUIS ALBERTO DIAZ (Johns Hopkins Medicine, Baltimore, USA)

GIANPIETRO DOTTI (North Carolina University, Chapel Hill, USA)

SOLDANO FERRONE (Harvard University, Boston, USA)

JOHN HISCOTT (Istituto Pasteur, Roma, Italy)

SERENELLA PUPA (Istituto Nazionale Tumori, Milano, Italy)

CLAUDIO TRIPODO (Università degli Studi di Palermo, Palermo, Italy)

Presentation

The 7th "Innovative therapy, monoclonal antibodies and beyond" Conference will collect leading international experts in the field of immuno-oncology and cancer cell signaling to understand the potential, opportunities and challenges of the immunotherapy and targeted therapies.

The key role of the immune system in cancer has been recognized for a long time. Our understanding of the co-evolution of cancer and the immune system has significantly improved, with significant results in clinic. Indeed, the increasing knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, allowed us to identify and apply more effective anti-cancer biological and immunological treatments. To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorithms of several different tumor types. Furthermore, elucidating resistance mechanisms and exploiting cancer vulnerabilities to therapeutics will ultimately improve cancer therapy and patient care.

This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.

Finally, several data supporting the combination of immunotherapies and standard treatments open an intriguing challenge, but also a real opportunity for the future therapeutic approaches.

Friday, 27 January 2017

WELCOME COFFEE

08.00-09.00 Registration

09.00-09.10 Welcome remarks of Authorities

G. Apolone, *Scientific Director of Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy)*

09.10-09.20 Introduction • **M. Di Nicola** (*Milan, Italy*)

I SESSION: Preclinical assays and novel biotargets

Chairman: F. de Braud (Milan, Italy), M. Di Nicola (Milan, Italy)

09.20-09.50 Mismatch repair and clonal neoantigens • **L.A. Diaz** (*Baltimore, USA*)

09.50-10.20 Immune and cancerous activities of matricellular proteins • **M. Colombo** (*Milan, Italy*)

10.20-10.50 Commensal bacteria drive extramucosal cancer progression by inducing interleukin-17-producing cells • **M. Bellone** (*Milan, Italy*)

10.50-11.20 Immunogenic cell death-inducing chemotherapies trigger PD-L1 dependent adaptive immune resistance to cancer • **L. Apetoh** (*Dijon, France*)

11.20-11.50 A Complement to cancer stromal microenvironment • **C. Tripodo** (*Palermo, Italy*)

11.50-12.10 General discussion

Keynote Lecture

12.10-12.55 HLA antigens modulation and response to immunocheck-point inhibitor immunotherapy • **S. Ferrone** (*Boston, USA*)

Introduced by: S. Pupa (Milan, Italy)

12.55-14.25 **BUFFET LUNCH**

II SESSION: Monoclonal antibodies, cell therapies and targeted molecules

Chairmen: **M. Del Vecchio** (Milan, Italy), **A. Anichini** (Milan, Italy)

- 14.25-14.55 New insights on CAR T-cells in solid tumors • **G. Dotti** (Chapel Hill, USA)
- 14.55-15.25 Combination strategies for the development of oncolytic virotherapies • **J. Hiscott** (Rome, Italy)
- 15.25-15.55 Combination immunotherapy: novel phase I studies • **M. Di Nicola** (Milan, Italy)
- 15.55-16.25 Immunotherapy and targeted therapy in melanoma: combination strategy
M. Del Vecchio (Milan, Italy)
- 16.25-17.00 Discussion
- 17.00 Conclusions • **M. Del Vecchio** (Milan, Italy)
- CME questionnaire compilation

General Informations

CONGRESS VENUE

Aula Magna Gianni Bonadonna
Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1 - MILAN

SCIENTIFIC COMMITTEE

Filippo de Braud

Michele Del Vecchio

Massimo Di Nicola

*Medical Oncology Department
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan*

ORGANIZING SECRETARIAT



Nadirex International Srl
Via Riviera 39 · 27100 Pavia
Tel. +39.0382.525714/35
Fax +39.0382.525736
E-mail: info@nadirex.com
www.nadirex.com

OFFICIAL LANGUAGE

English

CME PROVIDER NR. 265

Nadirex International Srl



CME

The request for CME credits has been submitted to the Italian Ministry of Health. **ID Nr. 265-176933 - CME credits: Nr. 7,3**

The Congress is intended for the following figures:

- **Physician** (*Ematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine*)

- **Biologist - Nurse - Biomedical laboratory technician**

Participants: 100.

In order to obtain CME credits, participants must:

- Attend 100% of the sessions indicated in the programme

- Fill in the personal data form, the form evaluating the event, and the learning questionnaire and give them to the Organizational Secretariat at the end of the Congress.

The CME certificate will be sent by mail after the Congress to the address given on the personal data form.

REGISTRATION

The registration is free and includes:


- Participation in the conference work • Congress Kit
- Certificate of Attendance • CME credits Certificate
- Welcome coffee and lunch as scheduled

REGISTRATION INSTRUCTIONS

The Congress provides for a maximum of 100 participants.

To register fill in and submit the registration form within **January 26th, 2017** by fax to nr. +39.0382.525736 or online at www.nadirex.com.

The Organizing Secretariat will confirm the registration by email.



Registration Form

Fill in using capital letters and send to:
 NADIREX INTERNATIONAL s.r.l.
 Via Riviera, 39-27100 Pavia
 Fax +39.0382.525736 - info@nadirex.com - www.nadirex.com

PLEASE COMPLETE THE FOLLOWING DETAILS

- PHISYCIAN
 BIOLOGIST
 NURSE
 BIOMEDICAL LABORATORY TECHNICIAN

Name Surname

Profession Discipline

Specialized

Clinic/Institute

Division/Department

Address

Postal Code Town/City Province

Tel. Fax

Mobile Tel.

E-mail

I authorise the use of my personal data in accordance with Legislative Decree 196/2003

Date Signature

SI RINGRAZIANO LE SEGUENTI AZIENDE
PER IL CONTRIBUTO NON CONDIZIONANTE:

AMGEN[®]

 Bristol-Myers Squibb

 **MSD**

 **NOVARTIS**

 Roche